Dual dopamine/serotonin releasers as potential medications for stimulante and alcohol addictions
Journal Title: The AAPS Journal - Year 2007, Vol 9, Issue 1
Abstract
We have advocated the idea of agonist therapy for treating cocaine addiction. This strategy involves administration of stimulant-like medications (eg, monoamine releasers) to alleviate withdrawal symptoms and prefent relapse. A major limitation, of this approach is that many candidate medicines possess significant abuse potential because of activation of mesolimbic dopamine (DA) neurons in central nervous system reward circuits. Previous data suggest that serotonin (5-HT) neurons can provide an inhibitory influence over mesolimbic DA neurons. Thus, it might be predicted that the balance between DA and 5-HT transmission is important to consider when developing medications with reduced stimulant side effects. In this article, we discuss several issues related to the development of dual DA/5-HT releasers for the treatment of substance use disorders. First, we discuss evidence supporting the existence of a dual deficit in DA and 5-HT function during withdrawal from chronic cocaine or alcohol abuse. Then we summarize studies that have tested the hypothesis that 5-HT neurons can dampen the effects mediated by mesolimbic DA. For example, it has been shown that pharmacological manipulations that increase extracellular 5-HT attenuate stimulant effects produced by DA release, such as locomotor stimulation and self-administration behavior. Finally, we discuss our recently published data about PAL-287 (naphthylisopropylamine), a novel non-amphetamine DA-/5-HT-releasing agent that suppresses cocaine self-administration but lacks positive reinforcing properties. It is conclude that DA/5-HT releasers might be useful therapeutic adjuncts for the treatment of cocaine and alcohol addiction, obesity, and even attention deficit disorder and depression.
Authors and Affiliations
Richard B. Rothman, Bruce E. Blough, Michael H. Baumann
Keywords
Related Articles
- EP ID EP681569
- DOI 10.1208/aapsj0901001
- Views 100
- Downloads 0
Development of a Complex Parent-Metabolite Joint Population Pharmacokinetic Model
This study aimed to develop a joint population pharmacokinetic model for an antipsychotic agent in development ({"type":"entrez-protein","attrs":{"text":"S33138","term_id":"423514","term_text":"pir||S33138"}} S33138) and...
Disposition of acetaminophen and indocyanine green in cystic fibrosis-knockout mice
Drug treatment poses a therapeutic challenge in cystic fibrosis (CF) because the disposition of a number of drugs is altered in CF. Enhanced clearance of acetaminophen (APAP) and indocyanine green (ICG) have previously b...
Effect of multivariate process instability on principal component analysis: A case study
With the rising use of principal component analysis/partial least squares (PCA/PLS) in the process analytical technology (PAT) initiative of the pharmaceutical industry, it seems appropriate to view that approach from a...
Simulation of Monoclonal Antibody Pharmacokinetics in HumansUsing a Minimal Physiologically Based Model
The online version of this article (doi:10.1208/s12248-014-9640-5) contains supplementary material, which is available to authorized users.
The back-step method—Method for obtaining unbiased population parameter estimates for ordered categorical data
A significant bias in parameters, estimated with the proportional odds model using the software NONMEM, has been reported. Typically, this bias occurs with ordered categorical data, when most of the observations are foun...